Expert consensus on the systemic treatment of atopic dermatitis

Abstract

Background: Atopic dermatitis (AD) is a chronic, systemic, inflammatory skin condition. In recent years, with increased understanding of the pathophysiology of AD, more disease-specific therapy options have become available. Objectives: This article presents recommendations developed by an expert panel of UK dermatologists on treatment choice, sequencing and bridging (overlapping conventional systemics with targeted therapies), in the new AD treatment landscape with newly approved biologics and Janus kinase inhibitors (JAKs). This manuscript also includes evaluation of the definition of moderate to severe disease. Method: These recommendations were generated after a detailed evaluation of the clinical trial data for dupilumab, tralokinumab, baricitinib, upadacitinib and abrocitinib. Insights were gathered using medCrowd, a digital advisory board technology. Results: A consensus opinion was developed by the authors discussing next steps in the evolving management of AD. Conclusion: The data shows that earlier intervention may reduce the risk of chronic disease status and optimise treatment response, thereby improving quality of life and reducing disease burden on the individual.